Showing results (41-50 of 261) with videos related to
Sort By:
Pageof 27
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 19, 2011
[Current status and future perspective of cancer vaccine development]Tetsuro Sasada, Kyogo ItohExpert Opinion on Biological Therapy|May 5, 2007
Peptide-based immunotherapeutic approaches to glioma: a reviewRyuya Yamanaka, Kyogo ItohThe Prostate|September 25, 2004
New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patientsAkihisa Yao, Mamoru Harada, Satoko Matsueda, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 11, 2007
[Acquired tumor "robustness" in the case of prostate cancer]Shigenori Homma, Masanori Noguchi, Yuji Sato, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 17, 2003
Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancersNaotake Tsuda, Kazuo Mochizuki, Mamoru Harada, et al.International Journal of Oncology|July 26, 2006
Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patientsShigenori Homma, Mamoru Harada, Hirohisa Yano, et al.Nihon Rinsho. Japanese Journal of Clinical Medicine|September 20, 2011
[Current status and prospects of cancer vaccine therapy]Takashi Mine, Yasuhiro Terazaki, Kyogo ItohCancer Immunology, Immunotherapy : CII|December 1, 2012
Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccineMasanori Noguchi, Tetsuro Sasada, Kyogo ItohCancer Science|February 2, 2018
Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte-specific protein tyrosine kinaseSatoko Matsueda, Kyogo Itoh, Shigeki ShichijoGan to Kagaku Ryoho. Cancer & Chemotherapy|May 24, 2016
[Chemotherapy and Anticancer Immune Responses]Mamoru HaradaPageof 27